EyeGage Selected as a Venture Atlanta 2022 Showcase Company

EyeGage Selected as a Venture Atlanta 2022 Showcase Company

Over $6.5 billion in funding awarded to date; leading tech investment conference continues to select large and diverse lineup of innovators from the Southeast’s hottest tech markets.

ATLANTA – September 20, 2022 – EyeGage announced today that it has been chosen out of a record-breaking 450-plus applicants as one of the top technology companies in the Southeast to be showcased at Venture Atlanta FORWARD 2022 on October 19-20. For 15 years, the annual conference has been selecting the most promising tech companies and bringing in the top investment firms from across the nation to hear them pitch. Venture Atlanta has helped launch more than 700 companies and raise $6.5 billion in funding to date, spinning out $17 billion in successful exits.

"We are excited to be showcased at Venture Atlanta 2022. We look forward to introducing our drug screening technology to investors and connecting with founders in the Southeast," says Dr. LaVonda Brown, Founder and CEO of EyeGage.

EyeGage allows high-risk workplaces to stay ahead of accidents with confidence—quickly and accurately screening for substances prior to operating equipment. The EyeGage solution saves time, money, and lives, while inherently reducing the negative impacts of substance abuse on families and communities. EyeGage runs on a mobile device that captures a snapshot of your eyes then assesses impairment.

As in previous years, Venture Atlanta FORWARD 2022 is anticipated to be a sold-out event, with over 1,200 entrepreneurs, founders, investors, and business leaders expected to be in attendance. A new venue for this year’s Venture Atlanta—the Woodruff Arts Center at 1280 Peachtree Street—reflects the growing intersection of art and technology.

“Venture Atlanta has established itself as the authority for recognizing technology innovation across the Southeast and beyond, connecting the best and brightest innovators with top-tier, national investors and other leaders in the tech ecosystem,” said Venture Atlanta CEO Allyson Eman. “We again set a new record with nearly 500 applicants for Venture Atlanta Forward 2022—it’s our most competitive year yet. With an impressive slate of 87 presenting and showcase companies, a record number of sponsors, and a brand-new venue, we’re continuing to raise the bar for what will be our 15th anniversary event.”

Venture Atlanta boasts a roster of highly successful alumni, including CallRail, Car360, Flock Safety, Florence Healthcare, Kabbage, ParkMobile, Pindrop Security, Salesforce Pardot, Salesloft, SingleOps, Stax, and Terminus.  

To learn more about EyeGage, visit www.eyegage.com. For additional information about Venture Atlanta, to register for the event, or to view the conference schedule, please visit www.ventureatlanta.org.

About EyeGage

The EyeGage technology seeks to shift current drug screening solutions by introducing a new method that uses computer vision to analyze characteristics of the eye. EyeGage employs AI recognition and analysis algorithms that can be deployed on any mobile device or computing apparatus with an embedded camera. Ultimately, the EyeGage drug screening technology will help prevent fatal accidents, make our communities safer, and save lives.

About Venture Atlanta

Venture Atlanta, the Southeast’s technology innovation event, is where the region’s most promising tech companies meet the country's top-tier investors. As the Southeast's largest investor showcase helping launch more than 700 companies and raise $6.5 billion in funding to date, the event connects the region’s top entrepreneurs with local and national investors and others in the technology ecosystem who can help them raise the capital they need to grow their businesses. The annual nonprofit event is a collaboration of the Atlanta CEO Council, Metro Atlanta Chamber, and the Technology Association of Georgia (TAG). For more information, visit www.ventureatlanta.org. For updates, follow us on Twitter and LinkedIn, and visit our blog.